Novartis has agreed to divest its “front of eye” ophthalmology assets to global health company Bausch + Lomb in a $2.5 billion deal, including $1.75 billion in cash upfront.
Novartis to divest assets to Bausch + Lomb for $2.5B
Novartis has agreed to divest its “front of eye” ophthalmology assets to global health company Bausch + Lomb in a $2.5 billion deal, including $1.75 billion in cash upfront.